Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1062502 | 0.75 | LMNA (1.00) | LMNAKDM4EUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17629492 | 0.74 | LMNA (0.65) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL2080394 | 0.72 | LMNA (0.70) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL19267501 | 0.71 | PKM (0.40) | LMNAKDM4EUSP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL17629552 | 0.71 | LMNA (0.68) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL17629578 | 0.71 | LMNA (0.68) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL26703221 | 0.69 | LMNA (0.70) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL17629568 | 0.68 | KDM4E (0.52) | KDM4EALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL2078683 | 0.68 | LMNA (0.62) | LMNAKDM5AKDM5BKDM4EUSP2 | |
| SCHEMBL26601966 | 0.68 | LMNA (0.56) | LMNAKDM5AKDM5BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3197455-B1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | MERCK SHARP & DOHME CORP. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2017-08-24 | — | — | US | disclosed |
| EP-3197455-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | Merck Sharp & Dohme Corp. (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016049097-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016045125-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016049097-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | MERCK SHARP & DOHME CORP. (US) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000501-B2 | Inhibitors of HIF prolyl hydroxylase | HIF1AN, HIF1A, EGLN2 | LMNA 3777/4885KDM5A 643/4885KDM5B 806/4885 |
| US-20170240555-A1 | INHIBITORS OF HIF PROLYL HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | LMNA 3777/4885KDM5A 643/4885KDM5B 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.